Diversity of effects of two antitumor anthracycline analogs on the pathway of activation of PKC in intact human platelets

C. Lanzi, P. Banfi, F. Ravagnani, R. A. Gambetta

Research output: Contribution to journalArticle

Abstract

Two antitumor antibiotics doxorubicin and daunorubicin were tested for their ability to influence the activation of protein kinase C in human platelets. Daunorubicin was found to inhibit the phosphorylation of the 40 K PKC substrate induced by thrombin and 12-O-tetradecanoyl-phorbol-13-acetate as well as the phosphorylation of the 20 K protein induced by thrombin. The serotonin release associated to these phosphorylative events was also inhibited by daunorubicin. In contrast the effects of doxorubicin, though inhibitory on the release reaction, were always stimulatory of the phosphorylations. Doxorubicin alone was able to induce the phosphorylation of both 40 K and 20 K phosphoproteins in a concentration-dependent manner. Whereas the stimulation by doxorubicin was not influenced by pretreatment with dibutyril-cyclic-AMP which inhibits the effects of thrombin, this effect was inhibited by daunorubicin, neomycin and stimulated by the diacylglycerol-kinase inhibitor R 59 022. It is proposed that doxorubicin activates the protein kinase C by causing the breakdown of phosphoinositides.

Original languageEnglish
Pages (from-to)3497-3504
Number of pages8
JournalBiochemical Pharmacology
Volume37
Issue number18
DOIs
Publication statusPublished - Sep 15 1988

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Diversity of effects of two antitumor anthracycline analogs on the pathway of activation of PKC in intact human platelets'. Together they form a unique fingerprint.

  • Cite this